

Archives of **DERMATOLOGY**

Copyright© 1976 by the AMERICAN MEDICAL ASSOCIATION

VOL 112, NO. 11

NOVEMBER 1976

EDITORIAL

Eye Diseases Induced by Topically Applied Steroids

J. B. Howell, MD, Dallas 1529

ORIGINAL CONTRIBUTIONS

Photochemotherapy of Vitiligo

*John A. Parrish, MD; Thomas B. Fitzpatrick, MD;
Christopher Shea; Madhu A. Pathak, MB, PhD, Boston* 1531

Mixed Connective Tissue Disease

Wilfred Minkin, MD, Nathan Rabhan, MD, New York 1535

Dermatologic Manifestations of Schistosomiasis Mansonii

Victor M. Torres, MD, San Juan, PR 1539

Herpes Gestationis

*Kenneth C. Hertz, MD; Stephen I. Katz, MD, PhD, Bethesda, Md;
John Maize, MD; A. Bernard Ackerman, MD, New York* 1543

Prednisone Therapy for Alopecia Areata

*Robert J. Winter, MD; Frank Kern, MD;
Robert M. Blizzard, MD, Baltimore* 1549

CASE REPORTS

Skin Capillary Changes in Early Systemic Scleroderma

*Raul Fleischmajer, MD; Jerome S. Perlish, PhD;
Kala V. Shaw, MS; Donald J. Pirozzi, MD, Philadelphia* 1553

Pacinian Neurofibroma

*Bruce Bennin, MD; Sidney Barsky, MD;
Karanmal Salgia, MD, Chicago* 1558

Induction of Glycosuria and Hyperglycemia by Topical Corticosteroid Therapy

Edward C. Gomez, MD, PhD, Phillip Frost, MD, Miami Beach, Fla 1559

Allergic Contact Dermatitis From Ethyl Sebacate in Haloprogin Cream

Alan R. Berlin, DO, O. Fred Miller, MD, Danville, Pa 1563

Malignant Angioendothelioma

Amir H. Mehregan, MD, Harold E. Usndek, MD, Detroit 1565

Pseudomonas Botryomycosis

*Gregory F. Bishop, MD; Kenneth E. Greer, MD;
David A. Horwitz, MD, Charlottesville, Va* 1568

(Continued on page 1504)

EDITORIAL BOARD

Chief Editor
John H. Epstein, MD
450 Sutter Street
San Francisco 94108

Assistant Chief Editor
Kimie Fukuyama, MD
San Francisco

Assistant Chief Editor
Denny L. Tuffanelli, MD
San Francisco

Donald C. Abele, MD
Augusta, Ga

Harry L. Arnold, Jr., MD
Honolulu

Walter C. Lobitz, Jr., MD
Portland, Ore

Frederick D. Malkinson, MD
Chicago

Sigfrid A. Muller, MD
Rochester, Minn

W. Mitchell Sams, Jr., MD
Denver

John S. Strauss, MD
Boston

Morris Waisman, MD
Tampa, Fla

Gerald D. Weinstein, MD
Miami

CONTENTS—Continued

Coexistence of Benign Familial Pemphigus and Psoriasis Vulgaris

Michael R. Heaphy, MD, R. K. Winkelmann, MD, PhD, Rochester, Minn 1571

Disseminated Granuloma Faciale

Louis J. Rusin, MD; Howard V. Dubin, MD;
William B. Taylor, MD, Ann Arbor, Mich 1575

REVIEW ARTICLES

Malignant Atrophic Papulosis of Degos

Susan M. Howsden, MD; Steven J. Hodge, MD;
James H. Herndon, MD; Robert G. Freeman, MD, Dallas 1582

Disorders of Phagocyte Function

William L. Weston, MD, Denver 1589

THERAPEUTIC NOTE

Safety of Long-Term Tetracycline Therapy for Acne

Gordon C. Sauer, MD, Kansas City, Mo 1603

REGULAR DEPARTMENTS

Letters to the Editor 1610

Chlorpromazine Photoallergy Harry L. Arnold, Jr, MD, Honolulu. . . **Chlorpromazine and Drug Eruptions** Takeshi Horio, MD, Kyoto, Japan . . . **Pharmacokinetics of Salicylic Acid** James W. Cooper, Jr, PhD; Christopher T. Rhodes, PhD; Bruce K. Birmingham, Kingston, RI; J. Richard Taylor, MD, Miami . . . **Quinidine Photosensitivity** Robert J. Pariser, MD, David M. Pariser, MD, Miami, Fla . . . **Pseudomelanoma** William B. Reed, MD, Burbank, Calif, A. Bernard Ackerman, MD, New York . . . **Sezary-like Cells From Supernatant of Burkitt Lymphocyte Cell Culture** Shiro Noguchi, MD, PhD, Bernard N. Robinowitz, MD, Cleveland . . . **Lichen Planus and Bullous Pemphigoid** Stanley I. Rekant, MD, Fort Dix, NJ . . . **Methoxsalen and Multiple Basal Cell Carcinomas** Rigmor Møller, MD, Jette Howitz, MD, Copenhagen . . . **Nomenclature of Staphylococci and Micrococci** David J. Bibel, PhD; Raza Aly, PhD; Howard I. Maibach, MD, San Francisco; James J. Leyden, MD, Philadelphia; Henry R. Shinefield, MD; William A. Akers, MD, San Francisco; Joseph W. Burnett, MD, Baltimore . . . **Protection of Skin From Sun** M. Allen Forbes, Jr, MD, Austin, Tex, Ira Leo Schamberg, MD, Elkins Park, Pa . . . **A Variant of Ichthyosis** Steven R. Kohn, MD, New York . . . **Warty Dyskeratoma of the Leg** William D. Storino, MD; Bruce Bennin, MD; Raymond Vahl, MD, Chicago

News and Notes 1620

Books 1624

Instructions for Authors see September 1976, p 1208

Index to Advertisers 1632

SUBSCRIPTION RATES: The yearly rate of the ARCHIVES OF DERMATOLOGY is as follows: United States and US Possessions, one year, \$18; two years, \$28; all other countries, one year, \$28; two years, \$38. Special yearly price to residents, interns and medical students in the United States and US Possessions, \$9.

THE ARCHIVES OF DERMATOLOGY is published monthly by the American Medical Association, 535 N Dearborn St, Chicago, IL 60610, and is an official publication of the Association. Second-class postage paid at Chicago and at additional mailing office.

DESCRIPTION

Synalar® (fluocinolone acetonide) has the chemical name 6 α , 9 α -difluoro-16 α -hydroxyprednisolone-16, 17-acetonide.

Synalar® Solution 0.01%—contains 0.01% fluocinolone acetonide in propylene glycol with citric acid.

Synalar® Ointment 0.025%—contains 0.025% fluocinolone acetonide in white petrolatum.

Synalar-HP® Cream—contains 0.2% fluocinolone acetonide in a water-washable aqueous base of stearyl alcohol, cetyl alcohol, mineral oil, propylene glycol, sorbitan monostearate, polyoxyethylene sorbitan monostearate and citric acid, with methylparaben and propylparaben as preservatives.

Synemol™ (fluocinolone acetonide) has the chemical name 6 α , 9 α -difluoro-16 α -hydroxyprednisolone-16, 17-acetonide.

The vehicle is a water-washable aqueous emollient base of stearyl alcohol, cetyl alcohol, mineral oil, propylene glycol, sorbitan monostearate, polyoxyethylene sorbitan monostearate and citric acid.

INDICATIONS

For relief of the inflammatory manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Topical steroids are contraindicated in vaccinia and varicella.

Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Synalar-HP Cream should not be used on infants up to two years of age.

PRECAUTIONS

If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

If extensive areas are treated or if the occlusive technique is used, the possibility exists of increased systemic absorption of the corticosteroid and suitable precautions should be taken.

Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of their use in pregnant females has not absolutely been established. Therefore, they should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Topical steroids are not for ophthalmic use.

Synalar-HP Cream should not be used for prolonged periods and the quantity per day should not exceed 2 g of formulated material.

ADVERSE REACTIONS

The following local adverse reactions have been reported with topical corticosteroids: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneform eruptions, hypopigmentation.

Synalar Cream and Ointment, Synemol Cream.

The following may occur more frequently with occlusive dressings than without such therapy: maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

HOW SUPPLIED

Synalar® (fluocinolone acetonide)
Cream 0.025%—15, 60 g tubes; 120, 425 g jars.
Cream 0.01%—15, 45, 60 g tubes; 120, 425 g jars.
Ointment 0.025%—15, 60 g tubes; 425 g jars.
Solution 0.01%—20, 60 cc plastic squeeze bottles.
Synalar-HP® (fluocinolone acetonide) 0.2% Cream—5, 12 g tubes.
Synemol™ (fluocinolone acetonide)
Cream 0.025%—15, 60 g tubes.

These preparations are available on prescription only.

SYNTEX
SYNTEX LABORATORIES, INC.
PALO ALTO, CALIFORNIA 94304